Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
Abbvie, Advisor, alphabetical, AML, asinter, AVEO, begun, bladder, Blue, Carbogen, Citigroup, customer, CytomX, declared, depict, Ellie, Euro, frame, fulfill, Harrison, IDEXX, IGN, Island, johnston, KAITLIN, KRISTINE, lesser, masking, Michigan, monotherapy, myeloid, notable, Oxford, partway, PDC, Pharmacology, PhD, PHS, presence, probody, reciprocal, relapsed, relinquished, Rhode, Shield, shortly, sublicensed, surface, tubulin, urinary, week, weekly, whichever
Removed:
Abgenix, acquired, Acting, advancing, Alnylam, ANDA, bioavailability, biochemical, broader, carcinoid, certification, chemical, clinic, complicated, Dentistry, device, differentiated, Elixir, EMILIA, hematological, humanization, humanizing, immune, immunoconjugate, Institute, invalidity, ion, landlord, larger, literature, lorvotuzumab, lymphoblastic, MCC, Merkel, mertansine, MM, moiety, murine, neuroendocrine, nonperformance, origin, pertuzumab, prohibit, resistance, Rochester, SCLC, sponsored, TAP, Theresa, toxicology, unrealized, Wingrove
Filing tables
Filing exhibits
Related press release
IMGN similar filings
Filing view
External links
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-3 No. 333 174335) of ImmunoGen Inc., and
(2) Registration Statements (Form S-8 No. 333-170788, 333-185086, 333-75372, 333-75374, 333-138713, 333-147738 and 333-155540) of ImmunoGen Inc.;
of our report dated August 28, 2014, with respect to the consolidated financial statements and schedule of ImmunoGen Inc. and the effectiveness of internal control over financial reporting of ImmunoGen Inc. included in this Annual Report (Form 10-K) of ImmunoGen Inc. for the year ended June 30, 2014.
/s/ Ernst & Young LLP
Boston, Massachusetts
August 28, 2014
Consent of Independent Registered Public Accounting Firm